Pasireotide Diaspartate
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Bariatric Hypoglycemia
Conditions
Post-Bariatric Hypoglycemia
Trial Timeline
Jan 4, 2024 → Apr 1, 2026
NCT ID
NCT05928390About Pasireotide Diaspartate
Pasireotide Diaspartate is a phase 2 stage product being developed by Recordati for Post-Bariatric Hypoglycemia. The current trial status is active. This product is registered under clinical trial identifier NCT05928390. Target conditions include Post-Bariatric Hypoglycemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05928390 | Phase 2 | Active |
Competing Products
1 competing product in Post-Bariatric Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| glucagon | Xeris Pharmaceuticals | Phase 1/2 | 36 |